Drug Profile
Research programme: antibodies - Enleofen
Alternative Names: Cytokine antibody - Enleofen; Interleukin 11 antibody therapeutics - Enleofen; Receptor antibody - EnleofenLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Duke-NUS Graduate Medical School Singapore; National Heart Centre Singapore
- Developer Enleofen
- Class Antibodies; Antifibrotics; Cardiovascular therapies; Hepatoprotectants
- Mechanism of Action Interleukin 11 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Singapore
- 28 Dec 2021 No recent reports of development identified for preclinical development in Fibrosis in Singapore
- 22 May 2019 Preclinical trials in Non-alcoholic steatohepatitis in Singapore (unspecified route) prior to May 2019